Seegene Strengthens Its European Reach with New French Subsidiary
Seegene, a prominent player in molecular diagnostics, is taking a significant step forward by establishing its eighth overseas sales subsidiary in France. This new venture marks the third such subsidiary in Europe, following successful launches in Italy and Germany.
The French market stands as Europe's second-largest in the field of molecular diagnostics, greatly propelled by the rising demand for testing related to sexually transmitted infections, gastrointestinal ailments, and respiratory viruses. Seegene's decision to expand its operations here is expected to enhance the adoption of its innovative solutions, namely CURECA™ and STAgora™.
Seegene's new subsidiary aims to bolster local engagement with customers and partners while providing enhanced technical support and strengthening market development initiatives in France. By fostering collaboration with various healthcare stakeholders, the company plans to improve service and responsiveness to local needs.
Recent studies indicate that France's molecular diagnostics market could reach around EUR 600 million, contributing approximately 15 percent of the entire European market. This positions France as a crucial location for Seegene's growth strategy, especially as they tap into high demand sectors for diagnostic tests that focus on STIs, gastrointestinal infections, and respiratory diagnostics.
According to Daniel Shin, Seegene's Executive Vice President and Chief Global Sales and Marketing Officer, the French market presents unique challenges and opportunities split between the public and private sectors. Achieving competitiveness requires swift delivery of innovative products that meet efficiency needs among laboratories. Through the new subsidiary, Seegene will better understand the dynamics of the French healthcare landscape, thereby enhancing service provisions and expanding its in vitro diagnostics business.
This strategic location also serves as a launching pad for Seegene's advanced solutions that are still in development. Among these are the fully automated, unmanned PCR system CURECA™, and STAgora™, which offers real-time diagnostic data analytics and predictive insights.
With the addition of this new subsidiary, Seegene now operates eight overseas sales offices worldwide, complementing its extensive network of 90 distributors across 94 countries. This expansion is pivotal as approximately 93 percent of Seegene's total revenue stems from international sales, with Europe contributing significantly at around 63 percent.
Seegene's experience in research and development spans over 25 years, focusing on syndromic real-time PCR technologies. Their expertise surfaced prominently during the COVID-19 pandemic, during which they distributed over 340 million COVID-19 tests to over 100 countries. Notably, Seegene's innovative technology allows simultaneous testing for up to 14 pathogens causing similar symptoms in a single tube, delivering quantitative results.
Seegene’s Commitment to Innovation
Seegene is dedicated to advancing healthcare through technology and innovative diagnostic solutions. The new French subsidiary signifies its commitment to furthering its impact in the European diagnostic market while addressing healthcare challenges with groundbreaking solutions. As the company continues to develop its product portfolio, customers can expect heightened efficiency in diagnostics and better health outcomes.
The Future of Molecular Diagnostics in Europe
The growing landscape of molecular diagnostics in Europe presents numerous opportunities for Seegene. As countries prioritize health initiatives and testing capabilities, Seegene is well-positioned to lead advancements in the marketplace. The establishment of local subsidiaries not only enhances service quality but also ensures that the company remains responsive to market dynamics and innovations.
Expanding Product Offerings
In addition to focusing on STIs and respiratory diagnostics, Seegene plans to diversify its offerings in the French market to include a wider range of product lines, targeting diseases such as cervical cancer and various multiplex diagnostic categories. This comprehensive approach is intended to meet the increasing demands of healthcare providers and patients alike.
Frequently Asked Questions
What is the purpose of Seegene’s new subsidiary in France?
The new subsidiary aims to enhance local market presence, improve customer support, and accelerate the adoption of its diagnostic solutions.
Why is France a significant market for Seegene?
France ranks as the second-largest molecular diagnostics market in Europe, driven by increasing demand for innovative diagnostic solutions.
What products will Seegene offer in France?
Seegene plans to offer a range of products, including those targeting STIs, respiratory infections, and multiplex diagnostics like cervical cancer testing.
How has Seegene performed internationally?
As of the first half of 2025, overseas sales accounted for about 93 percent of Seegene's total revenue, with Europe being a key contributor.
What innovative technologies does Seegene provide?
Seegene develops technologies like CURECA™, an automated PCR system, and STAgora™, a platform for real-time diagnostic analytics.
